US 12,234,239 B2
Crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile
Jingdan Hu, Greenfield, IN (US); and Timothy Andrew Woods, Greenfield, IN (US)
Assigned to Elanco US Inc., Greenfield, IN (US)
Filed by Elanco US, Inc., Greenfield, IN (US)
Filed on Jun. 2, 2022, as Appl. No. 17/830,898.
Application 17/830,898 is a division of application No. 16/855,471, filed on Apr. 22, 2020, granted, now 11,548,895.
Claims priority of provisional application 62/837,972, filed on Apr. 24, 2019.
Prior Publication US 2023/0056365 A1, Feb. 23, 2023
Int. Cl. A61K 31/519 (2006.01); A61P 17/00 (2006.01); A61P 37/08 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 17/00 (2018.01); A61P 37/08 (2018.01); C07B 2200/13 (2013.01)] 33 Claims
 
1. A crystalline form of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile of formula (I):

OG Complex Work Unit Chemistry
wherein the crystalline form is Form II;
wherein crystalline Form II of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile is characterized by a X-ray powder diffraction pattern comprising at least one characteristic peak (° 2θ) at 5.34°±0.2° 2θ, 10.68°±0.2° 2θ, 14.26°±0.2° 2θ, 16.06°±0.2° 2θ, 16.39°±0.2° 2θ, 16.48°±0.2° 2θ, 18.26°±0.2° 2θ, 18.65°±0.2° 2θ, 21.05°±0.2° 2θ, 21.76°±0.2° 2θ, 22.68°±0.2° 2θ, or 26.75°±0.2° 2θ; and wherein the X-ray powder diffraction pattern is determined on a diffractometer using CuKα radiation.
 
11. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the crystalline form of claim 1.